Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
0.060 PosttranslationalModification disease BEFREE The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype. 29468261 2019
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
0.060 PosttranslationalModification disease BEFREE Univariate analyses showed that patient age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component were prognostic of OS. 28682902 2017
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
0.060 GeneticVariation disease BEFREE A better prognosis was significantly associated with combined IDH1 mutation and MGMT methylation status (both positive vs both negative, HR 0.079 [95% CI 0.008-0.579], p=0.012), as well as histology (OG vs DA and OA, HR 0.158 [95% CI 0.022-0.674], p=0.011) and tumor size (<6 cm vs ≥6 cm, HR 0.120 [95% CI 0.017-0.595], p=0.008). 26276726 2015
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
0.060 PosttranslationalModification disease BEFREE In oligodendroglioma (OG) and oligoastrocytoma (OA), presence of 1p/19q codeletions is highly predictive of response to treatment and is often associated with the methylated MGMT promoter; hence, this study queries whether the presence of 1p/19q codeletions in OG/OA correlates with a higher rate of PsP following therapy. 24285548 2014
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
0.060 PosttranslationalModification disease BEFREE The EMP3 and MGMT promoter methylation was more frequent in OII than in GBM patients, and the IDH1 mutation was absent in GBM. 22992787 2012
Entrez Id: 4255
Gene Symbol: MGMT
MGMT
0.060 Biomarker disease BEFREE Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months. 16038527 2005